Abstract
Accumulating evidence and medical guidelines recommend high-dose neurorehabilitation for recovery after stroke. Unfortunately, most patients receive a fraction of this dose, with therapist availability and costs of delivery being major implementational barriers. To explore a potential solution, we conducted a retrospective analysis of a real-world enhanced clinical service that used gamified self-training technologies at home under remote therapist supervision.
Data from 17 patients who completed a 12-18 week full-body, high-dose neurorehabilitation program entirely at home were analyzed. Program delivery relied on patients independently training (asynchronously) with the MindMotion GO gamified-therapy solution. Accompanying telerehabilitation sessions with a therapist occurred weekly while therapists used a web application to monitor and manage the program remotely.
Patients maintained high training adherence throughout and reached an average total Active Training Time—a measure more closely reflecting delivered versus scheduled dose—of 39.7±21.4 hours, with the majority (82.2±10.8%) delivered asynchronously. Patients improved in both upper-limb (Fugl-Meyer, +6.4±5.1; p<0.01) and gait and balance measures (Functional Gait Assessment, +3.1±2.6; p<0.01; Berg Balance Scale, +6.1±4.4; p<0.01). Most experienced subjective improvements in physical abilities and overall satisfaction. Per-patient therapist costs approximated 338 USD, representing a resource-efficient alternative to delivering the same dose in-person (1903 USD).
This work demonstrates effective high-dose neurorehabilitation delivery via gamified therapy technologies at home and shows that training time can be successfully decoupled from therapist-presence without compromising adherence, outcomes, or patient satisfaction. Given growing concerns over therapist availability and increasing health care costs, this resource-efficient approach can help achieve medical guidelines and complement existing clinic-based approaches.
Competing Interest Statement
All authors have completed an ICMJE uniform disclosure form. SAA is an independent researcher contracted by MindMaze; DP, JTM, and GR have a research service agreement with MindMaze; MCC, AEF, and LTD are employed by MindMaze; DP and JTM are board members of Precision Recovery Inc; All other authors declare no other relationships or activities that could appear to have influenced this work.
Funding Statement
This study was funded by MindMaze
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Mount Sinai Program for the Protection of Human Subjects institutional review board of Icahn School of Medicine at Mount Sinai, New York, U.S.A. gave ethical approval for this work (STUDY-21-00345).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.